IC-265

N/A

Report date: 2024/12/11 16:59:26
NME

Base Information

Drug NameIC-265
Drug Alias NameIC-265IC265
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsUveitisDry Eye SyndromesXerophthalmia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesIACTA Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesZhaoke (Hong Kong) Ophthalmology Pharmaceutical LtdIACTA Pharmaceuticals IncZhaoke (Guangzhou) Ophthalmology Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsUveitisXerophthalmiaConjunctivitis, Allergic
Inactive IndicationsDry Eye Syndromes

Other Information

ATC CodeN/A
Related LinksN/A